Skip to content
Baret News – Lifestyle
Author:
Palvella Therapeutics Inc.
Palvella Therapeutics Announces New Data from the Phase 2 TOIVA Trial of QTORIN™ Rapamycin in Cutaneous Venous Malformations Presented at the 83rd Annual Meeting of the Society for Investigative Dermatology
May 21, 2026
Palvella Therapeutics Announces Uplisting to the Nasdaq Global Market
May 21, 2026
Palvella Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 7, 2026
Palvella Therapeutics Announces First Patients Dosed in Phase 2 LOTU Trial of Fast Track-Designated QTORIN™ Rapamycin for Clinically Significant Angiokeratomas
May 4, 2026
Palvella Therapeutics to Host First Quarter 2026 Financial Results and Corporate Update Conference Call on May 7, 2026
April 30, 2026
←
Previous Page
1
2
3